UCB (OTCMKTS:UCBJY) Sets New 12-Month High - Time to Buy?

Key Points

• UCB SA shares reached a new 52-week high of $107.91 during trading, closing at $105.90 with a volume of 91,640 shares.
• Goldman Sachs upgraded UCB to a "strong-buy" rating, reflecting positive expectations for the company's future growth.
• The company's financial metrics indicate a debt-to-equity ratio of 0.30 and a current ratio of 1.36, suggesting a strong financial position.

UCB SA (OTCMKTS:UCBJY - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $107.91 and last traded at $105.90, with a volume of 91640 shares. The stock had previously closed at $106.80.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded shares of UCB to a "strong-buy" rating in a report on Wednesday, July 16th.

UCB Stock Performance

The company has a current ratio of 1.36, a quick ratio of 0.99 and a debt-to-equity ratio of 0.30. The company's 50-day simple moving average is $97.11 and its 200-day simple moving average is $93.53.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.